Pay in 4 interest-free payments of $6.51 Learn more
Ships within 48 hours · Estimated delivery Aug 8 - Aug 13
10.1038/nature05292 Nature 279 LinY
The trial, known as SURPASS-2, showcased significant enhancements in fasting markers of islet cell function and insulin sensitivity across the modified intent-to-treat population
These findings position GLP-1RAs as a potential fourth pillar of kidney-protective therapy in diabetes, alongside renin-angiotensin system inhibitors (RASi), SGLT2i, and finerenone, and suggest a shift toward rapid initiation of combination therapies for maximum kidney protection
46 KimT
US$ 25.93
US$ 23.17
US$ 20.80
US$ 22.69
US$ 22.34
US$ 26.66
US$ 23.93
US$ 28.38
US$ 27.37
US$ 22.32
